Key Findings:
- The analysis compared WES-measured TMB with commercially available targeted panel estimates of TMB and found discordance in 10-15% of cases, with error rates correlating to panel size.
- In discordant cases, WES TMB more accurately predicted overall survival in pembrolizumab-treated patients than panel-based estimates.
- In a subset of ‘TMB reliant’ patients (n = 3,981), for example, patients with tumor types that lack disease-specific immune checkpoint inhibitor indications, the median overall survival in discordant cases was about five months longer for WES TMB-High and panel TMB-Low compared to WES TMB-Low and panel TMB-High cases treated with pembrolizumab.